• Home
  • Technology
  • Pipeline
    • Intranasal Naloxone
    • Intranasal Epinephrine
  • About us
  • Contact
  • News
Menu
  • Home
  • Technology
  • Pipeline
    • Intranasal Naloxone
    • Intranasal Epinephrine
  • About us
  • Contact
  • News

News

nasusphrma taffix

Nasus pharma presented clinical results at Fourth Annual – ASPN Conference, July 14-17, Miami Beach

July 28, 2022

CLICK HERE

Read More
nasusphrma taffix

Nasus Pharma presented clinical results of intranasal epinephrine in EAACI, July 2022, Prague

July 28, 2022

A Novel Faster‑Acting, Dry Powder‑Based, Naloxone Intranasal Formulation for Opioid Overdose

Read More
nasusphrma taffix

Nasus Pharma announces publication of its pivotal study comparing its FMXIN001 powder nasal Naloxone to Narcan®

April 12, 2022

A Novel Faster‑Acting, Dry Powder‑Based, Naloxone Intranasal Formulation for Opioid Overdose

Read More

More News

nasusphrma taffix

Nasus pharma presented clinical results at Fourth Annual – ASPN Conference, July 14-17, Miami Beach

July 28, 2022
nasusphrma taffix

Nasus Pharma presented clinical results of intranasal epinephrine in EAACI, July 2022, Prague

July 28, 2022
nasusphrma taffix

Nasus Pharma announces publication of its pivotal study comparing its FMXIN001 powder nasal Naloxone to Narcan®

April 12, 2022
nasusphrma taffix

Nasus Pharma Announces Positive Results from a Pilot Clinical Study of FMXIN002 Intranasal Powder Epinephrine Spray in

June 23, 2021
  • Home
  • News
  • Technology
  • Pipeline
  • About us
  • Contact us
  • Privacy policy
  • Cookies policy
  • Terms And Conditions Of Use

© 2021 All rights reserved